RegulatoryJul 15, 2026, 09:17 AM
Regentis Gets EU Approval for GelrinC Process; 400% Production Boost
AI Summary
Regentis Biomaterials Ltd. announced it has received European regulatory approval for a new solvent-free manufacturing process for its GelrinC® hydrogel implant. This approval significantly boosts production yield by 400%, delivering five times more product from the same volume while lowering manufacturing costs and improving scalability. The development is a key milestone as the company prepares for the commercial launch of GelrinC® in Europe, where it already holds CE Mark approval for knee cartilage repair.
Key Highlights
- Regentis received European regulatory approval for a new GelrinC manufacturing process.
- The new solvent-free process increases production yield by approximately 400% (5-fold).
- The approval lowers manufacturing costs and improves efficiency and scalability for GelrinC.
- This is a crucial step for the upcoming commercial launch of GelrinC in Europe.
- GelrinC is a CE Mark approved, cell-free hydrogel implant for knee cartilage repair.
- The U.S. market for knee cartilage repair is valued at $3 billion.
- A pivotal U.S. FDA study for GelrinC is currently over 50% enrolled.
Price Impact
More from RGNT